株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

世界の心筋マーカーアナライザー市場:製品分析、企業の事業・マーケティング戦略、主要取引

Global Cardiac Marker Analyzer Market, Product Analysis, Companies Business & Marketing Strategy, Major Deals

発行 iGate Research Pvt Ltd 商品コード 553477
出版日 ページ情報 英文 114 Pages
即納可能
価格
本日の銀行送金レート: 1USD=110.56円で換算しております。
Back to Top
世界の心筋マーカーアナライザー市場:製品分析、企業の事業・マーケティング戦略、主要取引 Global Cardiac Marker Analyzer Market, Product Analysis, Companies Business & Marketing Strategy, Major Deals
出版日: 2018年09月10日 ページ情報: 英文 114 Pages
概要

世界の心筋マーカーアナライザー市場は、2025年までに43億米ドルを上回ると予測されています。

当レポートでは、世界の心筋マーカーアナライザー市場について調査分析し、セグメント別の評価、比較テストの分析、競合製品の分析、製品の機能と利点、M&A、戦略的提携と企業の事業・マーケティング戦略など、体系的な情報を提供しています。

第1章 エグゼクティブサマリー

第2章 世界の心筋マーカーアナライザー市場と予測

第3章 心筋マーカー企業:比較テストの分析

第4章 心筋マーカーアナライザー:競合製品の分析

第5章 Alere (現 Abbott)

  • Alere トリアージ

第6章 Quidel Corporation

  • Quidel トリアージシステム

第7章 Abbott Point of Care

  • i-STAT システム

第8章 Roche

  • Cobas h 232 POC システム

第9章 Beckman Coulter

  • Access 2 イムノアッセイシステム

第10章 Siemens Healthineers

  • Stratus CS アナライザー

第11章 Response Biomedical

  • 心血管検査
  • RAMP プラットフォーム
  • Response 心血管検査

第12章 Boditech

  • i-chroma DUO アナライザー

第13章 Lifesign

  • DXpress Reader アナライザー

第14章 LSI Medience Corporation

  • PATHFAST アナライザー

第15章 CardioGenics Holdings Inc.

  • QL Care アナライザー

第16章 Trinity Biotech

  • Meritas POC アナライザー

第17章 M&A、ライセンス契約

  • Alere Inc
  • CardioGenics
  • Response Biomedical
  • Abbott Laboratories
  • Siemens Healthineers
  • LSI Medience Corporation
  • Trinity Biotech
  • Quidel

第18章 新興の市場

第19章 Response Biomedical:事業・マーケティング戦略

第20章 Roche:事業・マーケティング戦略

第21章 Boditech Med Inc:事業・マーケティング戦略

第22章 Siemens Healthineers:事業・マーケティング戦略

目次

The global Cardiac Marker Analyzer market is projected to exceed USD 4.3 Billion by 2025. Cardiac Marker analyzer represents a paradigm in diagnostics that provides high sensitivity and reliable information in minutes. It is ideally suited to both point of care testing and laboratory use. Cardiac biomarkers are used as risk stratification for various cardiovascular diseases (CVDs), which include myocardial infraction, congestive heart failure, acute coronary syndrome (ACS) among others. The cardiac biomarkers that are widely used as an integrated diagnostic approach for CVDs include CK-MB, troponin I and T, myoglobin, BNPs, IMA and few others. The prevention of cardiac diseases by monitoring the heart conditions via cardiac biomarker testing is the profound approach for obtaining rapid results for immediate diagnosing and treatment.

The factors such as increasing incidences of cardiovascular diseases, rapidly increasing geriatric population, growing funding from public-private organizations for research on cardiac biomarkers, and ongoing clinical trials for the identification of novel cardiac biomarkers are driving the growth of the market. However, factors such as technical problems related to sample collection and storage and issues related to regulatory and reimbursement systems are some of the key factors hampering the growth of this market.

Key Highlights of the Report:

  • In October 2017, Abbott completed its acquisition of Alere, concluding a deal first announced in February 2016.
  • In 2017, Abbott Point of Care Diagnostics sales increased by 7.2 percent.
  • Cobas H232 POC system permits rapid and easy determination of cardiac blood markers such as Troponin T, NT-proBNP, D-dimer, CK-MB and myoglobin.
  • Quidel's cardiac immunoassay revenue was close to US$ 50 Million in 2017.
  • A major focus of Response Biomedical development programs in cardiovascular testing has been clinical tests for the quantification of cardiovascular markers.
  • In February 2017, Siemens Healthineers announced a digital platform for healthcare providers as well as for providers of solutions and services.
  • CardioGenics is the only company to successfully deploy CL in a compact, fully automated POC platform.
  • Trinity Biotech Point-of-Care revenues for 2017 is likely to decline.
  • In Jan. 2017, Abbott completed the acquisition of St. Jude Medical, Inc., establishing the company as a leader in the medical device arena.
  • Response Biomedical sells tests that detect three of the primary markers for the detection of an acute myocardial infarction: Troponin I, Myoglobin and CK-MB.

iGATE RESEARCH report titled “Global Cardiac Marker Analyzer Market, Product Analysis, Companies Business & Marketing Strategy, Major Deals” provides a comprehensive assessment of the cardiac markers analyzer segments, comparative tests analysis, competitive product analysis, product features & benefits, merger & acquisitions, strategic alliances and Companies Business and Market Strategies.

This 114 Page report with 9 Figures and 19 Tables has been studied from 7 View Points:

  • 1. Cardiac Marker Analyzer Market & Forecast (2011 - 2025)
  • 2. Cardiac Marker Companies - Comparative Tests Analysis
  • 3. Cardiac Marker Analyzer - Competitive Product Analysis
  • 4. Cardiac Marker Analyzer - Specifications, Product Features & Benefits Analysis
  • 5. Cardiac Marker Analyzer - Mergers, Acquisitions, Distribution, Partnership and Licensing Agreements
  • 6. Emerging Markers Analysis
  • 7. Companies Business & Marketing Strategy

12 Cardiac Marker Analyzer Covered in the report are as follows:

  • 1. Triage MeterPro Analyzer
  • 2. The i-STAT System
  • 3. Cobas h 232 POC System
  • 4. Access 2 Immunoassay System
  • 5. Stratus CS Analyzer
  • 6. RAMP 200
  • 7. RAMP Reader
  • 8. i-chroma DUO Analyzer
  • 9. DXpress Reader Analyzer
  • 10. PATHFAST Analyzer
  • 11. QL Care Analyzer
  • 12. Meritas POC Analyzer

Cardiac Marker Analyzer - Key Companies Analysis

  • 1. Alere (Now Abbott)
  • 2. Abbott Point of Care
  • 3. Quidel Corporation
  • 4. Roche
  • 5. Beckman Coulter
  • 6. Siemens Healthineers
  • 7. Response Biomedical
  • 8. Boditech
  • 9. Lifesign
  • 10. LSI Medience Corporation
  • 11. CardioGenics Holdings Inc.
  • 12. Trinity Biotech

Data Sources:

iGATE RESEARCH employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports. This report is built by using data and information sourced from Proprietary Information Database, Primary and Secondary Research Methodologies, and In house analysis by iGATE Research dedicated team of qualified professionals with deep industry experience and expertise.

Research Methodologies:

  • Primary Research Methodologies: Questionnaires, Surveys, Interviews with Individuals, Small Groups, Telephonic Interview, etc.
  • Secondary Research Methodologies: Printable and Non-printable sources, Newspaper, Magazine and Journal Content, Government and NGO Statistics, white Papers, Information on the Web, Information from Agencies Such as Industry Bodies, Companies Annual Report, Government Agencies, Libraries and Local Councils and a large number of Paid Databases.

Table of Contents

1. Executive Summary

2. Global Cardiac Marker Analyzer Market & Forecast (2011-2025)

3. Cardiac Marker Companies-Comparative Tests Analysis

4. Cardiac Marker Analyzer-Competitive Product Analysis

5. Alere (Now Abbott)

  • 5.1. Alere Triage
    • 5.1.1. Alere Cardiology Net Sales (2010-2016)

6. Quidel Corporation

  • 6.1. Quidel Triage system
    • 6.1.1. Quidel Cardiac Immunoassay Net Sales (2017)

7. Abbott Point of Care

  • 7.1. The i-STAT System
  • 7.2. Abbott Laboratories Point of Care Diagnostics Sales (2011-2024)

8. Roche

  • 8.1. Cobas h 232 POC System

9. Beckman Coulter

  • 9.1. Access 2 Immunoassay System

10. Siemens Healthineers

  • 10.1. Stratus CS Analyzer
  • 10.2. Siemens Healthineers establishes global Digital Ecosystem to drive Digitalization of Healthcare

11. Response Biomedical

  • 11.1. Cardiovascular Testing
    • 11.1.1. Acute Myocardial Infarction (Heart Attack) Testing
    • 11.1.2. Congestive Heart Failure (“CHF”) Testing
    • 11.1.3. Thrombotic Disease Testing
  • 11.2. RAMP Platform
    • 11.2.1. RAMP 200
    • 11.2.2. RAMP Reader
  • 11.3. Response Cardiovascular Testing
    • 11.3.1. RAMP® TROPONIN I
    • 11.3.2. RAMP® NT-proBNP
    • 11.3.3. RAMP® MYOGLOBIN
    • 11.3.4. RAMP® CK-MB
    • 11.3.5. RAMP® D-DIMER
    • 11.3.6. Response Biomedical Cardiovascular Net Sales (2010-2024)

12. Boditech

  • 12.1. i-chroma DUO Analyzer

13. Lifesign

  • 13.1. DXpress Reader Analyzer

14. LSI Medience Corporation

  • 14.1. PATHFAST Analyzer

15. CardioGenics Holdings Inc.

  • 15.1. QL Care Analyzer

16. Trinity Biotech

  • 16.1. Meritas POC Analyzer
  • 16.2. Trinity Biotech Point of Care Diagnostics Sales (2010-2024)

17. Mergers, Acquisitions and Licensing Agreements

  • 17.1. Alere Inc
  • 17.2. CardioGenics
  • 17.3. Response Biomedical
  • 17.4. Abbott Laboratories
  • 17.5. Siemens Healthineers
  • 17.6. LSI Medience Corporation
  • 17.7. Trinity Biotech
  • 17.8. Quidel

18. Emerging Markers

19. Response Biomedical-Business & Marketing Strategy

  • 19.1. New Distributors in China
  • 19.2. Strategic Alliances with Alere Medical in Japan
  • 19.3. Response Biomedical Receives Health Canada Approval and CE Mark
  • 19.4. Focus on Improving Efficiencies and Reducing Costs

20. Roche-Business & Marketing Strategy

  • 20.1. Implementing the Fully Connected Core Laboratory
  • 20.2. Broadening the Diagnostics Portfolio
  • 20.3. Roche Launches Point-Of-Care (POC) Troponin Test with Improved Accuracy
  • 20.4. Roche Launches New Mobile Application for Tablets

21. Boditech Med Inc-Business and Marketing Strategy

  • 21.1. Boditech Med Acquires Immunostics
  • 21.2. Marketing Channel

22. Siemens Healthineers-Business and Marketing Strategy

  • 22.1. Siemens Healthineers Announces New Strategic Relationship
  • 22.2. Cloud-Based Network Teamplay from Siemens Healthineers
  • 22.3. Strategic Partnership between Siemens and Imricor
  • 22.4. Siemens Healthineers Offers True High-Sensitivity Troponin I IVD Assay
  • 22.5. Siemens Healthineers Establishes Global Digital Ecosystem to Drive Digitalization of Healthcare
  • 22.6. Partnership between Siemens Healthineers and Ebit

List of Figures:

  • Figure 2-1: Global - Cardiac Marker Analyzer Market (Million US$), 2011 - 2017
  • Figure 2-2: Global - Forecast for Cardiac Marker Analyzer Market (Million US$), 2018 - 2025
  • Figure 5-1: Global - Alere Cardiology Net Sales (Million US$), 2010 - 2016
  • Figure 7-1: Global - Abbott Laboratories Point of Care Diagnostics Sales (Million US$), 2011 - 2017
  • Figure 7-2: Global - Forecast for Abbott Laboratories Point of Care Diagnostics Sales (Million US$), 2018 - 2024
  • Figure 11-1: Global - Response Biomedical Cardiovascular Product Sales (Million US$), 2010 - 2017
  • Figure 11-2: Global - Forecast for Response Biomedical Cardiovascular Product Sales (Million US$), 2018 - 2024
  • Figure 16-1: Global - Trinity Biotech Point of Care Diagnostics Sales (Million US$), 2010 - 2017
  • Figure 16-2: Global - Forecast for Trinity Biotech Point of Care Diagnostics Sales (Million US$), 2018 - 2024

List of Tables:

  • Table 3-1: Cardiac Marker Companies - Comparative Tests Analysis
  • Table 3-2: Cardiac Marker Companies - Comparative Tests Analysis
  • Table 3-3: Cardiac Marker Companies - Comparative Tests Analysis
  • Table 4-1: Cardiac Marker Analyzer - Competitive Product Analysis
  • Table 4-2: Cardiac Marker Analyzer - Competitive Product Analysis
  • Table 5-1: Alere - Triage Product Analytes
  • Table 14-1: PATHFAST - Technical Specifications
  • Table 17-1: Alere - Merger & Acquisition, 2007 - 2017
  • Table 17-2: Alere - Distribution/Partnership Agreement, 2008, 2016
  • Table 17-3: CardioGenics - Mergers & Acquisition, 2015
  • Table 17-4: CardioGenics - Licensing Agreement, 2012
  • Table 17-5: Response Biomedical - Distribution Agreement, 2011 - 2015
  • Table 17-6: Response Biomedical - Collaboration Deal, 2004 - 2015
  • Table 17-7: Abbott Laboratories - Merger & Acquisition, 2003, 2017
  • Table 17-8: Siemens Healthineers - Merger & Acquisition, 2017
  • Table 17-9: Siemens Healthineers - Strategic Partnership, 2017
  • Table 17-10: LSI Medience Corporation - Strategic Alliance, 2014
  • Table 17-11: Trinity Biotech - Merger & Acquisition, 2012
  • Table 17-12: Quidel Corporation - Merger & Acquisition, 2017
Back to Top